



Bhagiradha Chemicals & Industries Limited.

Unit No.1011A, Level 1, Sky One (Wing A),
Prestige SkyTech, Financial District,
Nanakramguda, Hyderabad - 500032,
Telangana, INDIA.

Tel : +91-40-65440409

Fax: +91-40-23540444

E-Mail: info@bhagirad.com

Ref: BCIL/SE/2025/42

May 29, 2025

To,
The Secretary,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, C-1, G Block, Bandra-Kurla,
Complex, Bandra (East), Mumbai – 400 051

Scrip Code: 531719

Symbol: BHAGCHEM

Sub: Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith Investors Presentation on the Financial Highlights for the quarter and financial year ended March 31, 2025.

The copy of the same is also available on the website of the Company i.e.
<https://www.bhagirad.com>

Kindly take the same on record and display on the website of your exchange.

For **Bhagiradha Chemicals and Industries Limited**

Sharanya. M

Company Secretary & Compliance Officer

M. No: ACS-63438

Encl: a/a



Bhagiradha Chemicals & Industries Limited

Investor Presentation – May 2025



This presentation and the accompanying slides (the “Presentation”), which have been prepared by Bhagiradha Chemicals and Industries Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks.

The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections

Company Overview

Bhagiradha at a Glance

30+ years establishment

Established in **1993** by visionary entrepreneur, late Sri. S. Koteswara Rao who was well recognised scientist in South India

Unique Proposition

Backward integration to basic chemicals and **faster adaptation to new chemistries** is the core strength applied across multiple products

Manufacturing facilities

2 manufacturing facilities at Andhra Pradesh (existing) & Karnataka (upcoming)

Capacity at existing facility is **3,250 MT**
Capacity of upcoming facility is **9,000 MT**

Product Portfolio

Established Capacity of 32

Active Ingredients, Intermediates & Formulations


Strong Customer base

Long-standing relationship of 10+ years with top customers in domestic and international markets


Robust R&D infrastructure

One of the few R&D focused active ingredient players in India - **Tactically curated product basket comprising 'Exclusive' and 'Complex' products**


Revenue (Rs. In Cr.)



EBITDA (Rs. In Cr.)



PAT (Rs. In Cr.)



BCIL is well-established, trusted and respected name in the Agrochemical space whose DNA is to Deliver Quality products on consistent basis

Transformational Journey so far

BCIL 1.0

1993 - 2004

FY04
Revenue:
52 crores

- **1993:** Founded by Sri Koteswara Rao, a well-recognized scientist in South India.
- **1995:** Set-up manufacturing plant and launched Chlorpyrifos as Flagship product.
- **1996:** Launched IPO and listed on BSE
- **1998:** Ventured into international regulated markets including EU, Australia, Peru and Costa Rica.
- **2002:** Founder's son, S. Chandrasekhar, joined the business.
- **2004:** Set-up 2nd manufacturing block and also launched a dedicated in-house R&D facility.
- **2004:** Launched herbicide Triclopyr for exports to Australia and insecticide Imidacloprid in domestic market.

2005 - 2011

FY11
Revenue:
60 crores

- **2005:** Started contract manufacturing for US based MNC.
- **2008:** Set up Block 3, enhancing capacity to 3,250 MT for manufacturing new molecules.
- **2009:** Commercialized Herbicide products Clodinafop Propargyl and Cloquintocet Mxy.
- **2010:** Launched insecticide Thiamethoxam.
- **2011:** Launched Azoxystrobin at N-1.

2012 - 2019

FY19
Revenue:
384 crores

- **2012:** Backward integration of Azoxystrobin to N-5 level.
- **2012:** Ventured into regulated markets of Brazil and EU.
- **2014-16:** Launched 3 new intermediates for contract manufacturing business for India and US market.
- **2017:** Expanded export markets by adding big ticket customers in regulated markets like US.


2020 - 2025

FY25
Revenue:
441 crores

- **2020:** backward integration of Azoxystrobin to N-7, highest among the Indian peers.
- **2021:** Evolved a large molecule - Fipronil at high backward integration level.
- **2023:** Turnover crossed Rs. 500 crores.
- **2024:** Commencement of operations of wholly owned subsidiary Bheema Fine Chemicals.
- **2025:** Introduced new product Trifloxystrobin.

BCIL 2.0


Growth Phase





- ✓ Commencement of operations of wholly owned subsidiary Bheema Fine Chemicals.
- ✓ Greenfield expansion with incremental capacity of 9,000 MTPA.
- ✓ New Products/molecule introduction.
- ✓ Further backward integration.
- ✓ Revenue Target of ~5x in next 6 to 7 years with operating efficiency and better margin profile.

With Product Launches at Regular Intervals

*Products Capability






Top 5 Products Revenue Contribution (%)



***Over the years successfully launched 30+ Active Ingredients, Intermediates & Formulations at regular intervals, through strong in-house R&D, reflecting the innovative mindset of the leadership and R&D team**


and Established Customer Base



Along with Strong Market Presence

Presence in 20+ countries - Serving the farming communities worldwide

Manufacturing Plants in Andhra Pradesh & Karnataka (India)




>80% of exports sales in **regulated markets**

Andhra Pradesh (Existing Plant)

- **No. of production blocks:** 3 production blocks with 4 process lines
- **Capacity:** 3,250 MT / p. a.
- **Capacity Utilization:** ~80%
- **No. of products manufactured in an year:** 7-10

Karnataka (New Plant)

- **No. of production blocks:** 2 production blocks with 5 process lines (proposed)
- **Capacity:** 9,000 MT/p.a.
- **No. of products proposed to be manufactured in a year:** 10- 14



Production blocks are equipped to manufacture multiple products as per business requirement

- **Quality infrastructure :** Well, laid out infrastructure with assured water supply by KIADB, with no dependency on outside water supply
- **Access to work force:** Proximity to key towns, help in sourcing skilled manpower
- **Cost savings on waste disposal:** Availability of TSDF inside industrial area, leading to reduced transport cost related to waste disposal
- Zero liquid discharge effluent treatment facility

Bhagiradha's competitive edge

R&D serves as a growth engine, backed by strong infrastructure

Well-established R&D centre –

Approved by Department of Scientific and Industrial Research & Ministry of Technology and Science, Government of India

8 Synthesis labs with
60+ Chemists

R&D center,
Pilot and semi
commercial plant

- Establishing an R&D lab for new product development, a pilot plant for sample production, and semi-commercial plant to support early-stage commercialization.
- Pursuing joint R&D initiatives with leading multinational partners from Japan, the US, and Israel

- **New Process development:** Developing synthesis routes for off-patent and upcoming off-patent molecules
- **Off Patent Products:** Developing cost-effective, non-infringing processes for off-patent molecules
- **Backward Integration:** Enhancing backward integration of products to match leading global active ingredient players
- **Library of Reactions:** Designing versatile manufacturing facilities capable of 25+ chemistries and 120+ reactions proven in R&D
- **Launch Complex Products in Quick Turnaround Time:** Competency to develop complex products from lab to production scale; with quick turnaround time



R&D Facility – Synthesis, Kilolab & Process Safety Lab

- Process development for new products and optimization studies for existing products
- Generation of product samples and impurities to support registration process
- Process safety studies



Pilot Plant

- Scaling of process up to 25 kg per batch
- Generation of product samples to support registration process
- Scale-up studies for technology transfer to semi-commercial / commercial plant




Semi – Commercial Plant

- Batch reactors, autoclave, condensers, etc. that can produce up to 250 kg/batch
- Support customer campaigns and enabling customer feedback to support future commercial scale campaigns

Creating Entry Barrier: Backward Integration

Future backward integration
Backward integrated inputs




Future backward integration planned to N-7 with 13 process stages, which is expected to increase the margins

~4%
Global Market share

~14%
Domestic Market share

Backward integration to increase to N-9 level with 16 process stages by FY 26, thus increasing margin

Imports
~60%



We intend to backward integrate in all the key future products on similar lines

~6%
Global Market share

~27%
Domestic Market share

Launched the product with high level of backward integration right from the start, commanding a high margin.
Allowed to operate at competitive pricing and capture the market

Imports
~23%

Environmentally Responsible & Validated by Customers & External Agencies

Greenery around plant



Green Belt



ETP



Audit by Reputed External Agencies



- Ground water quality assessment (2020, 2022, 2024)
- Odor Assessment Report (2022)



- Off-site emergency plan (2021)



- Safety audit (2019)



- Risk assessment and disaster management planning

Effluent Treatment Plant

- Zero Liquid Discharge (ZLD) ETP which recycles water for reuse. ~30% of daily water requirement is catered through recycling
- Organic waste generated is sent to authorized cement plant for co-incineration while Inorganic solid waste is disposed to APPCB* approved secured landfill
- Biological sewage treatment plant has been set up for treatment of domestic wastewater

01

Electro Oxidation Plant

- Effluent treatment process based on electro-oxidation technology implemented for first time in an agrochemical facility
- Highly effective process for treatment of Chemical Oxygen Demand (COD) in waste waters which improve the quality of recycle water

02

Pollution Control Measures

- Multi-stage scrubbers installed to control gaseous emission
- Mechanical dust collector, bag filter and stack of adequate height provided for boilers to control suspended particulate matter (SPM)
- Online Continuous Monitoring Systems (OCMS) installed as per the CPCB and APPCB guidelines

03


Fire Safety Measures

- Nitrogen breathing systems installed for all bulk storage tanks (flammable solvents) and process equipment to ensure inert atmosphere (fire safety)
- Continuous earth monitoring systems installed to ensure the earth bonding to ensure no static charge accumulation
- Fire hydrant systems implemented as per Tariff Advisory Committee guidelines


04

BCIL 2.0

Growth Investment



will have Exponential Growth




- ✓ Leveraging existing relationships to capture markets & adding new customers through competitiveness pricing & ability to offer high quality products
- ✓ Launching new products which are globally top selling molecules in their respective categories with significant level of backward integration.
- ✓ New products expected to have higher margins because of the limited competition, first mover advantage & high level of backward integration
- ✓ Partnering with innovators on exclusive basis by leveraging our product development capabilities.
- ✓ Ability to decode complex chemistries and develop non-infringing processes within a reasonable turnaround time.
- ✓ Preferred partner in regulated markets by virtue of its intellectual property rights in respect of certain processes

Increase level of backward integration in existing key molecules so as to have minimum dependency on Chinese imports thereby improving the margins

Expand product portfolio by developing and introducing new off-patent and High Margin Products along with focus on higher level of backward integration

To be established as a sizeable and stable segment with higher margins. Working closely with few multinationals


Improve efficiency through yield enhancement, improvement in reactor volume throughput, lowering power cost through Solar investments.




Q4 & FY25 Result Highlights

Consolidated Financial Highlights


Revenue From Operations




EBITDA




PAT




Gross Margin (%)



EBITDA Margin (%)



PAT Margin (%)



Revenue:

- Volume led growth
- Average price realizations remained muted throughout the year for some of our products. Steps have been taken to optimize product mix to ensure higher price realisation in the coming quarters

EBITDA:

- Largely impacted due to Increase in employee cost and reduction in gross margin from products
- Hiring in Bheema facility to be ready for full scale commercial operations of phase 1 shortly
- Costs incurred on account of strengthening R&D team

PAT:

- Drag due to overall lower operating profits
- Increase in depreciation due to new facility
- Higher working capital requirements reflected higher interest costs on account of delayed payments from customers

Consolidated Profit & Loss Statement

| Particulars (Rs. In Cr.) | Q4FY25 | Q4FY24 | YoY | Q3FY25 | QoQ | FY25 | FY24 | YoY |
|--------------------------------|--------|--------|------|--------|------|-------|-------|------|
| Revenue From Operations | 122.6 | 111.3 | 10% | 102.7 | 19% | 440.5 | 407.6 | 8% |
| Cost of Raw Materials Consumed | 83.7 | 66.0 | | 61.8 | | 278.1 | 246.6 | |
| Gross Profit | 38.9 | 45.2 | -14% | 40.9 | -5% | 162.3 | 161.0 | 1% |
| Gross Profit Margin (%) | 31.7% | 40.7% | | 39.9% | | 36.9% | 39.5% | |
| Employee Benefit Expenses | 11.0 | 8.8 | | 9.8 | | 40.7 | 33.3 | |
| Other Expenses | 21.8 | 22.3 | | 22.0 | | 84.7 | 84.8 | |
| EBITDA | 6.1 | 14.1 | -57% | 9.2 | -34% | 36.9 | 42.9 | -14% |
| EBITDA Margin (%) | 5.0% | 12.7% | | 8.9% | | 8.4% | 10.5% | |
| Depreciation & Amortization | 3.6 | 2.9 | | 3.6 | | 13.9 | 11.0 | |
| EBIT | 2.5 | 11.2 | -78% | 5.6 | -55% | 23.1 | 31.9 | -28% |
| Interest Expense | 1.6 | 2.1 | | 2.4 | | 7.1 | 7.7 | |
| Other Income | 1.3 | 1.5 | | 2.4 | | 9.3 | 2.7 | |
| Exceptional Gain/Loss | 0.0 | 0.0 | | 0.0 | | 0.0 | 0.0 | |
| Profit Before Tax | 2.2 | 10.6 | | 5.6 | | 25.2 | 26.9 | |
| Tax Expense | 3.1 | 3.3 | | 2.0 | | 11.4 | 8.7 | |
| Profit After Tax | -0.9 | 7.2 | NA | 3.6 | NA | 13.9 | 18.2 | -24% |
| Profit After Tax Margin (%) | NA | 6.5% | | 3.5% | | 3.1% | 4.5% | |

Consolidated Balance Sheet

| Assets (Rs. In Cr.) | Mar-25 | Mar-24 |
|-------------------------------------|--------------|--------------|
| Non- Current Assets (A) | 558.3 | 295.8 |
| Property, Plant & Equipment | 238.2 | 213.7 |
| Capital Work in Progress | 287.8 | 65.5 |
| Right use of Assets | 5.0 | 0.2 |
| Intangible Assets | 1.7 | 0.1 |
| Intangible Assets under Development | 1.4 | 2.1 |
| Financial Assets | | |
| (i) Others Financial Assets | 5.9 | 7.1 |
| Other Non-Current Assets | 18.3 | 7.0 |
| Current Assets (B) | 374.9 | 280.3 |
| Inventories | 129.7 | 111.5 |
| Financial Assets | | |
| (i) Trade Receivables | 173.9 | 107.1 |
| (ii) Investments | 0.0 | 38.5 |
| (iii) Cash & Cash Equivalent | 28.8 | 9.9 |
| (iv) Bank Balance other than Cash | 1.0 | 1.0 |
| (v) Others Financial Assets | 0.3 | 0.4 |
| Current Tax Assets (net) | 0.1 | - |
| Other Current Assets | 41.1 | 11.9 |
| Total Assets (A+B) | 933.2 | 576.0 |

| Equity & Liabilities (Rs. In Cr.) | Mar-25 | Mar-24 |
|--|--------------|--------------|
| Equity (A) | 682.2 | 413.7 |
| Equity Share Capital | 13.0 | 10.4 |
| Other Equity | 669.3 | 403.3 |
| Non-Current Liabilities (B) | 55.7 | 36.8 |
| Financial Liabilities | | |
| (i) Borrowings | 30.0 | 16.9 |
| (ii) Other Financial Liabilities & Lease Liabilities | 4.0 | 1.1 |
| Provisions | 0.2 | 0.0 |
| Deferred Tax Liabilities (net) | 21.4 | 18.7 |
| Current Liabilities (C) | 195.3 | 125.5 |
| Financial Liabilities | | |
| (i) Borrowings | 54.4 | 44.5 |
| (ii) Trade Payables | 93.2 | 65.3 |
| (iv) Other Financial Liabilities & Lease Liabilities | 39.7 | 13.5 |
| Other Current Liabilities | 3.1 | 0.8 |
| Provisions | 2.9 | 1.2 |
| Current Tax Liabilities (net) | 2.0 | 0.3 |
| Total Equity & Liabilities (A+B+C) | 933.2 | 576.0 |

Consolidated Cash Flow Statement

| Particulars (Rs. In Cr.) | Mar-25 | Mar-24 |
|--|----------------|----------------|
| Net Profit Before Tax | 25.2 | 26.9 |
| Adjustments for: Non -Cash Items / Other Investment or Financial Items | 10.9 | 15.0 |
| Operating profit before working capital changes | 36.2 | 41.9 |
| Changes in working capital | (81.8) | (2.8) |
| Cash generated from Operations | (45.6) | 39.1 |
| Direct taxes paid (net of refund) | (7.2) | (4.8) |
| Net Cash from Operating Activities | (52.8) | 34.3 |
| Net Cash from Investing Activities | (200.0) | (120.6) |
| Net Cash from Financing Activities | 271.7 | 88.3 |
| Net Decrease in Cash and Cash equivalents | 18.9 | 2.0 |
| Effect of exchange differences | 0.0 | 2.9 |
| Add: Cash & Cash equivalents at the beginning of the period | 9.9 | 4.9 |
| Cash & Cash equivalents at the end of the period | 28.8 | 26.9 |



A. Arvind Kumar
Executive Director & CEO

"The full year FY25 marked a period of stable volume expansion, despite broader market challenges. However, pricing pressures persisted throughout the year, primarily due to oversupply from Chinese competitors. This was particularly evident in the fourth quarter, where select product prices declined by ~15–20%. Despite the challenging market environment, our revenue from operations grew modestly by 8% year-over-year, with raw material prices moderating, but not enough to offset the pronounced decline in price realizations. Consequently, PAT declined by 24% year-on-year, impacted by subdued pricing in key products, elevated input costs, and operational losses at a new subsidiary.

Despite ongoing global challenges and pricing headwinds, early signs of demand recovery are encouraging. We've seen a strong rebound in volumes, and with pricing likely having bottomed out, we anticipate a gradual improvement beginning in the second half of FY26. Industry-wide, pricing stability and volume recovery are already gaining momentum.

The capex plan remain firmly on track, with Phase I expected to be operational by June–July 2025, followed by a ramp-up period of 12–18 months. The full impact of this phase is anticipated to reflect in FY27 performance. During the quarter/year, we also expanded our product portfolio with the launch of two new offerings in the insecticides and fungicides segments, reinforcing our market presence and supporting long-term growth.

As we step into FY2025–26, we remain committed to executing our strategic roadmap. With introduction of new products, continued focus on backward integration, increasing manufacturing capacity through greenfield expansion, and deepening R&D capabilities, we are well-positioned to capture emerging opportunities and navigate the evolving global agrochemical landscape. We remain optimistic about the long-term prospects of the business and are fully committed to delivering sustained value to our stakeholders."

FY25 Key Highlights

- We have witnessed a strong volume recovery since Q2 FY25, driven by increased demand and market expansion
- In Q3 FY25, our volumes growth has been near double digit compared to the same period last year, reflecting exceptional growth momentum
- In Q4 FY25, volume growth continued, profitability impacted due to pricing pressures for some key products
- During the year we launched 2 new products - one in insecticide and one in fungicide

Capex Update

- Total expansion plan of ~Rs. 800 crore, including a ~Rs. 100 crore for solar project
- For Phase 1, an estimated capital investment of ~Rs. 385 crore, ~Rs. 376 crore was utilized as of March 2025; structured ramp-up over the next 12–18 months
 - Aiming 5 to 8 new & existing molecules, with higher gross material margin
- Phase 2 yet to operationalise; expected to commence by Q1 FY27, with an estimated capital investment of ~Rs. 350 crore

Recommended final dividend of Rs. 0.15 per equity share of face value of Rs. 1/- each (i.e. 15 %) for FY25, subject to shareholders approval



Thank You!

Company:



CIN: L24219TG1993PLC015963

Mrs. Sharanya. M - Company
Secretary & Compliance Officer
cs@bhagirad.com

+91-40-42221212 / 42212323 /
23540616
www.bhagirad.com

Investor Relations Advisors:



CIN: U74140MH2010PTC204285

Ms. Neha Shroff / Mr. Mayur Pednekar
neha.shroff@sgapl.net /
mayur.Pednekar@sgapl.net

+91 77380 73466 / +91 70213 26784
www.sgapl.net

Annexure



**Late Singavarapu
Koteswara Rao**

Scientist Founder

- Late Sri Koteswara Rao was one of the well-recognized scientists in South India. His years of hard work, research and innovative mindset have spurred the growth and success of BCIL.
- He held a postgraduate degree in Chemical Engineering from IIT Madras.
- He started his career working in research related roles at global reputed institutes. He joined University of Stuttgart, Germany as a research fellow, after which he played a key role as production engineer at Chemische WerkeHuels AG for 6 years.
- After a successful stint in Germany, Mr. Rao returned to India and joined as a Senior Scientist at Indian Institute of Chemical Technology, Hyderabad.
- In 1988, he co-promoted Vantech Industry Limited to set up a Monocrotophos plant.
- He founded BCIL in 1993 along with his former colleague. He steered the company to success as its Managing Director.
- Under his leadership, BCIL became an internationally respected agrochemical player in a short period of time.

Have Strong Leadership Team



S. Chandrasekhar
Promoter & Managing Director

- Inspired by his father and owing to his keen interest and aptitude for research, he joined the company in 2002 as its R&D Manager.
- He took charge as BCIL's Managing Director in 2012 and played a significant role in the success of BCIL over the last few years.
- Holds a Master's degree in chemical engineering from University of Illinois, Chicago, USA and a degree in Chemical Engineering from Osmania University.



A. Arvind Kumar
Executive Director & CEO

- 20+ years of experience in the chemical industry including designing and setting up of chemical plants.
- Joined the group in 2007; moved as COO in 2014, and then promoted as CEO in May 2019, became a whole time Director since August 2023
- Holds Postgraduate degree in Chemical Engineering from IIT – Madras and graduated in Chemical Engineering from Osmania University.



B. Krishna Mohan Rao
Chief Financial Officer

- Graduate in Arts and Associate of the Indian Institute of Banking & Finance.
- 35+ years of experience Corporate finance function, Commercial and SME banking.
- Responsible for the financial operations of the Company, and legal & regulatory compliances.



Dr. Venkatesan Subbusamy
**Vice President - Regulatory Affairs
& Registration**

- Holds a PhD degree in Entomology from the University of Madras.
- Associated with BCIL since 2022.
- Prior to joining BCIL, Dr Subbusamy held senior positions in UPL, NACL and ZIBO NAB Agrochemicals, China.
- Responsible for product registration in India and overseas geographies.



Sharanya M.
**Company Secretary &
Compliance Officer**

- Mrs. Sharanya. M is a Qualified Company Secretary, Member of the Institute of Company Secretaries of India (ICSI) and a Law Graduate.
- With over 5+ years of experience in Secretarial, Legal, Regulatory Compliances and Corporate laws.
- She is responsible for ensuring compliance with Secretarial, Statutory and legal requirements while promoting effective corporate governance practices.

Experienced Board Members



Kishor Shah
Non-executive Chairman

- Board member since 2020.
- 30+ years of experience in various senior positions in Finance and Accounts.
- Associated with Balrampur Chini Mills Ltd. for over 21 years as its CFO and as a Board member.
- He is a Fellow Member of the Institute of Chartered Accountants of India.



GSV Krishna Rao
Independent Non-executive Director

- Board member since 2018.
- 30+ years of experience and retired in the position of a General Manager in a nationalized bank.



Dr. G. Aruna
Independent Non-executive Women Director

- Board member since 2020.
- 27+ years of professional experience in Engineers India Limited and SABIC Research and Technology Pvt Ltd.
- She holds a B. Tech., M.Sc. (Chem Engineering) and PhD in Chem Engineering from Indian Institute of Science, Bangalore.

Non-Independent Directors



S. Chandrasekhar
Managing Director

- Immediately on completion of his Master's in Chemical Engineering from the University of Illinois, Chicago, being passionate in Chemical Research, began his career as Manager, R&D in BCIL and rose to the position of MD in 2012.
- A good number of generic products have been commercialized in BCIL under his guidance and with his active participation in developing non-infringing process technologies.
- Under his leadership as the MD since 2012, BCIL scaled new heights in terms of turnover and profits and gained recognition for its R&D capabilities.



L. S. Singavarapu
Non-Independent Non-Executive Director

- Board member since 2014.
- Involved in the activities relating to the employees and the matters relating to Corporate Social Responsibility.
- She is a Postgraduate in Commerce from Osmania University.



A. Arvind Kumar
Executive Director & CEO

- 20+ years of experience in the chemical industry including designing and setting up of chemical plants.
- Joined the group in 2007; moved as COO in 2014, and then promoted as CEO in May 2019, became a whole time Director since August 2023.
- Holds a Postgraduate degree in Chemical Engineering from IIT – Madras and graduated in Chemical Engineering from Osmania University..




Suresh Kumar Somani
Non-Independent Non-executive Director


- The Founder and Joint Managing Director of Ratnabali Group.
- He is an entrepreneur, investor and philanthropist with a substantial experience of over 40 years in the equity market.
- He is a commerce graduate from St Xavier's college, Kolkata.

Historical Performance


Revenue From Operations (Rs. In Cr.)




EBITDA (Rs. In Cr.)




Profit After Tax (Rs. In Cr.)




Revenue Break-up (%)






EBITDA (%)



PAT (%)




Expense Snapshot




Cost of overheads in percentage terms is higher, owing to lower revenue in FY2024

Key Ratios

Return on Capital Employed (%)




Asset turnover ratio





Working Capital (No. of Days)



Return on Equity (%)



Debt to Equity Ratio



ROCE and ROE appear lower as the fund raised for the subsidiary’s project are under deployment and improvements shall be reflected upon achieving full scale operations

Assets turnover is lower due to Investments are done in subsidiary, expected to be operationalize from this year

Corporate Action Update – Convertible warrants issued on preferential basis

Warrants issued in November 2023

| Particulars | | Remarks |
|---------------------------------|----------------|--|
| No. of shares Issued & Allotted | 25,61,425 | Equity shares of Rs. 10/- each |
| Price | Rs. 1,332/- | Incl. premium of Rs. 1,322/- per share warrant |
| Total | Rs. 340 crores | - |
| Upfront Payment | 25% | Equity warrants amounting to Rs. 85.30 Crores |

Subdivision of Shares: May 2024:


The existing equity shares of the Company of face value of Rs. 10/- have undergone sub-division/split into 10 equity shares of face value of Re. 1/- each fully paid up.

| Particulars (May-24) | Pre-conversion of securities | | | | Post-conversion of securities | |
|---------------------------|------------------------------|--|---|---------------|--|--|
| | Total no. shares held | Shareholding as a % of total no. of shares | No. of Shares Underlying- Outstanding convertible securities (including Warrants) | % | No. of Shares (assuming full conversion of convertible securities) | Shareholding as a % assuming full conversion of convertible securities |
| Promoter & Promoter Group | 2,44,73,640 | 23.52% | 11,26,100 | 4.4% | 2,55,99,740 | 19.74% |
| Public | 7,95,81,190 | 76.48% | 2,44,88,150 | 95.6% | 1,04,06,9340 | 80.26% |
| Total | 10,40,54,830 | 100% | 2,56,14,250 | 100.0% | 12,96,69,080 | 100.00% |

Warrants Fully Subscribed

Proceeds will be channeled into investments for growth purpose in the subsidiary company – Bheema Fine Chemicals Private Limited

Capital Raise History



Rs. In Crores

Cumulative promoters participation is to the tune of Rs. 51 crores into company